戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 actor that acts on plasma membrane cysteinyl leukotriene receptors.
2  Our data show that LTB4, via its receptor B leukotriene receptor 1 (BLT1) and Galphai signaling, inc
3 B4 act through activation of its receptor, B leukotriene receptor 1 (BLT1).
4 ompounds with dual activity toward cysteinyl leukotriene receptor 1 (CysLT(1)R) and G-protein-coupled
5 ease in cell-surface expression of cysteinyl leukotriene receptor 1 (CysLT1) as determined by flow cy
6 rthermore, LTD4 plus PGE2, through cysteinyl leukotriene receptor 1 (CysLT1R) and E-prostanoid recept
7 thma pathogenesis, in part through cysteinyl leukotriene receptor 1 (CysLT1R).
8 " neutrophil subset that expressed cysteinyl leukotriene receptor 1 (CysLTR1) and produced TNF, CCL2,
9 )2 cells might selectively express cysteinyl leukotriene receptor 1 (CYSLTR1) mRNA.
10  pharmacological inhibition of the cysteinyl-leukotriene receptor 1 (CYSLTR1) protects cerebrocortica
11           We functionally assessed cysteinyl leukotriene receptor 1 protein (CysLT(1)) expression usi
12  and montelukast, an antagonist of cysteinyl leukotriene receptor 1.
13 tory cells and their expression of cysteinyl leukotriene receptors 1 and 2 (CysLT(1) and CysLT(2)) an
14 genic small molecule antagonist of cysteinyl leukotriene receptors 1 and 2 (CysLT1 and CysLT2).
15 get VEGF receptors but antagonizes cysteinyl leukotriene receptors 1 and 2 (CysLT1-2) at micromolar I
16                                            B leukotriene receptor-1 (BLT-1), the primary LTB4 recepto
17 ing the G protein-coupled receptor cysteinyl-leukotriene receptor 2 (CysLTR2).
18 d a recurrent mutation in CYSLTR2 (cysteinyl leukotriene receptor 2) encoding a p.Leu129Gln substitut
19 ed signaling cascade downstream of cysteinyl leukotriene receptor 2.
20                 Stimulation of the cysteinyl leukotriene receptor activated CRAC channels and evoked
21 stain cytoplasmic Ca(2+) signaling following leukotriene receptor activation both by refilling the Ca
22 fter rundown of the Ca(2+) signals following leukotriene receptor activation, stimulation of P2Y rece
23 ukast (an antagonist of the type 1 cysteinyl leukotriene receptor) also inhibited E. coli invasion of
24 e as a dualistic uracil nucleotide/cysteinyl leukotriene receptor and by others as inactive toward th
25 ccelerated homologous desensitization of the leukotriene receptor and thereby terminated the oscillat
26 -lipoxygenase inhibition and sulfidopeptidyl leukotriene receptor antagonism on lumenal chemotaxis of
27                                              Leukotriene receptor antagonism resulted in a significan
28 steroid (ICS step-up therapy) or addition of leukotriene receptor antagonist (LTRA step-up therapy) o
29 ment with ICSs alone (n = 1758) or ICSs plus leukotriene receptor antagonist (LTRAs; n = 354) or ICSs
30 edication (long-acting beta2-agonist [LABA], leukotriene receptor antagonist [LTRA], theophylline, or
31  treatment with H1 and H2 receptor blockers, leukotriene receptor antagonist and consideration for pr
32 ge in FEV1 in the Characterizing Response to Leukotriene Receptor Antagonist and Inhaled Corticostero
33 ium Respimat added to ICSs with or without a leukotriene receptor antagonist in a phase III trial in
34 yclo-oxygenase inhibitor indomethacin or the leukotriene receptor antagonist MK-571, indicating that
35 o examine a potential protective role of the leukotriene receptor antagonist montelukast on future ri
36               New dispensed prescription for leukotriene receptor antagonist montelukast or control m
37            Second line therapies include the leukotriene receptor antagonist montelukast, and other a
38 ected animals with MC-stabilizing drugs or a leukotriene receptor antagonist restores vascular integr
39 ational method to titrate corticosteroid and leukotriene receptor antagonist therapy.
40 nist, long-acting muscarinic antagonist, and leukotriene receptor antagonist was hospitalized with a
41 choconstriction by a single oral dose of the leukotriene receptor antagonist zafirlukast was assessed
42  mouse model, we administered montelukast, a leukotriene receptor antagonist, and diabetes-related re
43    We aimed to assess whether montelukast, a leukotriene receptor antagonist, can improve symptoms or
44 vide benefit if combined with montelukast, a leukotriene receptor antagonist, in patients whose sympt
45 he effectiveness of montelukast, a cysteinyl leukotriene receptor antagonist, in the treatment of pos
46 ceptor antagonist, cetirizine, and cysteinyl-leukotriene receptor antagonist, montelukast, as well as
47  for a daily inhaled corticosteroid, a daily leukotriene receptor antagonist, or a mast cell stabiliz
48             Montelukast, an oral, once-daily leukotriene receptor antagonist, provides protection aga
49 ecommend an intranasal corticosteroid over a leukotriene receptor antagonist.
50 d be blocked using a pharmacologic cysteinyl-leukotriene receptor antagonist.
51  leukotriene B4 receptor but not a cysteinyl-leukotriene receptor antagonist.
52 to ICS background therapy, with or without a leukotriene receptor antagonist; long-acting beta2-agoni
53 fluticasone twice daily plus 5 or 10 mg of a leukotriene-receptor antagonist daily (LTRA step-up).
54   We evaluated the ability of montelukast, a leukotriene-receptor antagonist, to protect such patient
55 without a low-dose inhaled glucocorticoid or leukotriene-receptor antagonist.
56 roids (21.5%; 95% CI: 20.7%-22.3%; p<0.001), leukotriene receptor antagonists (13.4%; 95% CI: 12.9%-1
57        Long-acting beta2-agonists (LABA) and leukotriene receptor antagonists (LTRA) are two principa
58 = 973), ICS monotherapy (n = 2623), ICS plus leukotriene receptor antagonists (LTRA; n = 338), or ICS
59                         The use of cysteinyl leukotriene receptor antagonists (LTRAs) for asthma ther
60                                The growth of leukotriene receptor antagonists (LTRAs) has been extrao
61     Recent evidence suggests that the use of leukotriene receptor antagonists (LTRAs) in addition to
62  describe here novel mechanisms of action of leukotriene receptor antagonists (LTRAs), outline how to
63 hieved by LABAs (improved lung function) and leukotriene receptor antagonists (LTRAs; protection agai
64                                              Leukotriene receptor antagonists and long-acting beta2-a
65 osteroids [topical (swallowed) or systemic], leukotriene receptor antagonists and, most recently, bio
66               Controlled trials suggest that leukotriene receptor antagonists can improve lung functi
67                                         Oral leukotriene receptor antagonists have been shown to have
68 agents such as cromolyn and the new class of leukotriene receptor antagonists have demonstrated benef
69 ukotriene synthesis inhibitors and cysteinyl leukotriene receptor antagonists have shown efficacy in
70 nical efficacy of inhaled glucocorticoids to leukotriene receptor antagonists in children with mild t
71 al need to use alternative therapies such as leukotriene receptor antagonists or DNase I that target
72                                              Leukotriene receptor antagonists such as montelukast hav
73  daily inhaled corticosteroids (ICSs), daily leukotriene receptor antagonists, and as-needed ICS trea
74 include daily inhaled corticosteroids, daily leukotriene receptor antagonists, and combination therap
75 ray of options, including H2 antihistamines, leukotriene receptor antagonists, glucocorticosteroids,
76 s, long-acting inhaled beta2-stimulants, and leukotriene receptor antagonists, increased year after y
77                                          The leukotriene receptor antagonists, montelukast, zafirluka
78 the approved dose) plus H(2)-antihistamines, leukotriene receptor antagonists, or both.
79  the approved dose plus H(2)-antihistamines, leukotriene receptor antagonists, or both.
80  useful add-on therapies for AR include oral leukotriene receptor antagonists, short bursts of a nasa
81 emists in the design of potent and selective leukotriene receptor antagonists-leukotriene structural
82 successfully identified clinically effective leukotriene receptor antagonists.
83 ing long-acting muscarinic antagonist and 13 leukotriene receptor antagonists.
84 a, which was treated with antihistamines and leukotriene receptor antagonists.
85 ticosteroids, long-acting beta-agonists, and leukotriene receptor antagonists.
86 mple, H1- and H2-antihistamines or cysteinyl leukotriene receptor antagonists.
87 ay disease include the use of muscarinic and leukotriene receptor antagonists; however, these pharmac
88 s, such as leukotriene synthesis inhibitors, leukotriene receptors antagonists, and more recently pro
89                                              Leukotriene-receptor antagonists (LTRAs) are recommended
90                                              Leukotriene-receptor antagonists are the first novel cla
91                                              Leukotriene-receptor antagonists as monotherapy improved
92                                              Leukotriene-receptor antagonists either as monotherapy o
93                Another potential spin-off of leukotriene-receptor antagonists is that they also seem
94                      The published data with leukotriene-receptor antagonists such as montelukast or
95 long-acting beta agonists, theophyllines, or leukotriene-receptor antagonists, adjusted stepwise acco
96                             The low affinity leukotriene receptor BLT2 is a receptor involved in pro-
97          Antagonists of the type 1 cysteinyl leukotriene receptor (CysLT(1)R) are efficacious for bro
98  and human fibrocytes express both cysteinyl leukotriene receptor (CysLT) 1 and CysLT2.
99                     Two classes of cysteinyl leukotriene receptor, CysLT(1) and CysLT(2), have been i
100 and characterization of the second cysteinyl leukotriene receptor, CysLT(2), a 346-amino acid protein
101          Antagonists of the type 1 cysteinyl leukotriene receptor (CysLT1R) are widely used to treat
102 in-coupled receptor 5 [TGR5]), and cysteinyl leukotriene receptor (CYSLTR) 1 are G-protein-coupled re
103 enes C4 associated with an overexpression of leukotrienes receptor CysLTR1 by asthmatic BSM cells in
104 kotriene B4 (LTB4R and LTB4R2) and cysteinyl leukotriene receptors (CYSLTR1 and CYSLTR2) contribute t
105  and a total absence of disease pathology in leukotriene receptor-deficient mice.
106                 Here we show that abolishing leukotriene receptor desensitization suppresses agonist-
107 s of diabetes for retinal histopathology and leukotriene receptor expression and 2) after 3 months of
108                                     Finally, leukotrienes receptor expression was assessed in vitro b
109 s the way for future clinical translation of leukotriene receptor inhibition for the treatment of dem
110  blotting for gene and protein expression of leukotriene receptors LT1-R and LT2-R, and for concentra
111 dministration has issued safety alerts about leukotriene receptor-modifying agents and suicidality/su
112 ing to replenish the PIP2 pool accessible to leukotriene receptors, ostensibly through control of PIP
113  a marketed anti-asthmatic drug antagonizing leukotriene receptors, reduces neuroinflammation, elevat
114 therosclerosis is associated with a specific leukotriene receptor(s) capable of inducing hyperreactiv
115     This work illustrates that inhibition of leukotriene receptor signalling might represent a safe a
116 erized the gene structure of human cysteinyl leukotriene receptor type I (cysLT(1)R).
117                            The expression of leukotriene receptors was deregulated in esophageal squa
118                                              Leukotriene receptors were examined by autoradiography,
119 ajor findings were: 1) protein levels of all leukotriene receptors were significantly increased in es

 
Page Top